Michael A. Weller

Michael A. Weller

Radiation Oncology

6780 Mayfield Rd
Mayfield Heights, OH 44124

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 736 publications

Loss of MSH6 or MSH2 sensitizes progressive glioblastoma to radiotherapy.

Loss of MSH6 or MSH2 sensitizes progressive glioblastoma to radiotherapy.

Journal: The Journal of clinical investigation

Published: August 25, 2026

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 02, 2026

Hypoxia-targeted BOLD MRI signal heterogeneity as a complementary metric for glioblastoma characterization: a pilot study.

Hypoxia-targeted BOLD MRI signal heterogeneity as a complementary metric for glioblastoma characterization: a pilot study.

Journal: Journal of neuro-oncology

Published: May 31, 2026

Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY).

Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY).

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 30, 2026

Intratumoral hemorrhage in patients with brain metastasis from systemic tumors: risk factors and prognostic assessment.

Intratumoral hemorrhage in patients with brain metastasis from systemic tumors: risk factors and prognostic assessment.

Journal: Journal of neuro-oncology

Published: May 25, 2026

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 22, 2026

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 07, 2026

The European Association for Neuro-oncology (EANO) Consensus Statement on Radiation Necrosis.

The European Association for Neuro-oncology (EANO) Consensus Statement on Radiation Necrosis.

Journal: Neuro-oncology

Published: May 05, 2026

Neurosurgeons' perspective on surgical treatment of glioblastoma: Practices, beliefs and willingness to randomize in surgical trials.

Neurosurgeons' perspective on surgical treatment of glioblastoma: Practices, beliefs and willingness to randomize in surgical trials.

Journal: Neuro-oncology advances

Published: May 01, 2026

Breast Cancer Patient Awareness and Reasons for Foregoing Breast Reconstruction. Early Findings From the ROSE (Breast Cancer and Reconstruction Outcome Survey) Study.

Breast Cancer Patient Awareness and Reasons for Foregoing Breast Reconstruction. Early Findings From the ROSE (Breast Cancer and Reconstruction Outcome Survey) Study.

Journal: Annals of plastic surgery

Published: April 26, 2026

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 14, 2026

ESTRO, ESNR and EORTC consensus-based definition for MRI abnormalities after radiotherapy for intracranial central nervous system tumours.

ESTRO, ESNR and EORTC consensus-based definition for MRI abnormalities after radiotherapy for intracranial central nervous system tumours.

Journal: Neuro-oncology

Published: April 13, 2026

Showing 1-12 of 736

Last Updated: 09/26/2026